ClinicalTrials.gg
CompletedNCT01111604Updated Aug 6, 2019Results posted

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

A Phase 2 interventional study of Ramucirumab and Icrucumab in Colon Cancer and Rectal Cancer, sponsored by Eli Lilly and Company. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-06.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Colonic Neoplasms by Eli Lilly and Company — none open to participants now, 4 under way, none of them phase 3. Colonic Neoplasms · Eli Lilly and Company.

Enrollment
4th of 10
158 · median 71
Started
2010
the only one that year
Phase 2
4 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Colonic Neoplasms by Eli Lilly and Company, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 2, and was the 4th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

None of the 11 studies in Colonic Neoplasms by Eli Lilly and Company is open now. The open studies under Colonic Neoplasms, anywhere →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Colonic Neoplasms by Eli Lilly and Company as a file.
02

Study summary

The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard chemotherapy plus icrucumab.

Read the detailed description

The purpose of this study is to evaluate the progression-free survival (PFS) in participants with metastatic colorectal cancer when treated with 1 of 3 modified FOLFOX-6 (folinic acid [FA] + fluorouracil [5-FU] + oxaliplatin [mFOLFOX-6])-based regimens, as second-line therapy.

During 2010, there has been an identified shortage of injectable folinic acid (FA) in the United States. Levo-folinic acid (LFA) will be allowed as a substitute for FA in the mFOLFOX-6 chemotherapy regimen in circumstances in which FA is not available, to facilitate continuity of participant care.

03

Conditions studied

  • Colon Cancer
  • Rectal Cancer

Keywords

  • Colonic Neoplasms
  • Rectal Neoplasms
  • Adenocarcinoma
  • Antibodies, Monoclonal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease progression on an irinotecan-based chemotherapy regimen (ie FOLFIRI or CAPIRI [capecitabine + irinotecan], with or without bevacizumab)
  • Age ≥ 18 years
  • of ≥ 6 months
  • Performance Status (ECOG PS) 0-1 at study entry
  • Agrees to adequate during the study period and for 12 weeks after the last dose of study medication
  • Provided signed

Exclusion criteria

Exclusion Criteria:

  • Has received prior oxaliplatin-based chemotherapy for locally advanced unresectable or Colorectal Cancer (CRC) (Prior oxaliplatin-based chemotherapy is allowed if the last dose of oxaliplatin was administered > 12 months prior to randomization)
  • Has documented and/or symptomatic brain or
  • Has an ongoing or active infection, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders
  • On chronic non-topical treatment. A participant discontinuing such treatment > 3 months prior to randomization is eligible
  • Has uncontrolled or poorly controlled hypertension on a standard regimen of antihypertensive therapy
  • Has a concurrent active . A participant with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years
  • If female, is pregnant (confirmed by serum beta human chorionic gonadotropin [βHCG] test) or lactating
  • Has received a prior autologous or allogeneic organ or tissue transplantation
  • Has undergone major surgery within 28 days prior to randomization
  • Has had a serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization
  • Has an elective or planned major surgery to be performed during the course of the trial
  • Has a history of inflammatory bowel disease requiring pharmacological and/or surgical intervention in the 12 months prior to randomization
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Active comparator
    mFOLFOX-6

    mFOLFOX-6

    Drug: mFOLFOX-6

  • Experimental
    mFOLFOX-6 + Ramucirumab

    mFOLFOX-6 + Ramucirumab

    Biological: Ramucirumab · Drug: mFOLFOX-6

  • Experimental
    mFOLFOX-6 + Icrucumab

    mFOLFOX-6 + Icrucumab

    Biological: Icrucumab · Drug: mFOLFOX-6

Interventions

  • BiologicalRamucirumab

    8 mg/kg IV Q2W

    Also known as: IMC-1121B, LY3009806

  • BiologicalIcrucumab

    15 mg/kg IV Q2W

    Also known as: IMC-18F1, LY3012212

  • DrugmFOLFOX-6

    Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W) FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable). 5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit.

    Time frame: Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)

Secondary outcomes

  1. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes \[target or non-target\] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression.

    Time frame: Baseline until Disease Progression (Up to 95 Weeks)

  2. Overall Survival (OS)

    Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.

    Time frame: Baseline Until Death from Any Cause (Up to 163 Weeks)

  3. Duration of Response (DoR)

    DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to \< 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.)

    Time frame: Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)

  4. Pharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5

    Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum.

    Time frame: Cycle 5, 1 Hour Post End of Infusion

  5. Pharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 5

    Trough (prior to infusion, Ctrough) concentrations measured in serum.

    Time frame: Cycle 5, Prior to Infusion

  6. Maximum Concentration (Cmax) at Day 8

    Maximum concentration (Cmax) is the maximum peak concentration measured in blood plasma after drug infusion.

    Time frame: Day 8 (cycles 1 and 5)

  7. Maximum Concentration (Cmax) at Day 15

    Cmax is the maximum peak concentration measured in blood plasma after drug infusion.

    Time frame: Day 15 (Cycles 1 and 5)

  8. Minimum Concentration (Cmin) at Day 1

    Cmin is the minimum peak concentration measured in blood plasma after drug infusion.

    Time frame: Day 1 (cycles 1, 5, 9, and 13)

  9. Minimum Concentration (Cmin) at Day 4

    Cmin is the minimum peak concentration measured in blood plasma after drug infusion.

    Time frame: Day 4 (cycles 1 and 5)

  10. Minimum Concentration (Cmin) at Day 8

    Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.

    Time frame: Day 8 (cycles 1 and 5)

  11. Minimum Concentration (Cmin) at Day 15

    Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.

    Time frame: Day 15 (cycles 1 and 5)

  12. Number of Participants With Serum Ramucirumab Antibody Assessment

    A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.

    Time frame: 31 Weeks

  13. Serum Anti-Icrucumab Antibody Assessment

    A sample will be considered positive for anti-icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-icrucumab antibody level seen in healthy untreated individuals.

    Time frame: 31 Weeks

  14. Number of Participants With Adverse Events

    A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to 165 weeks

07

Results

Posted Aug 6, 2019

Participant flow

Participant flow — Overall Study
MilestonemFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Started545252
Received at least one dose of study drug495252
Completed465249
Not completed803
Withdrew: Lost to follow-up001
Withdrew: Withdrew consent302
Withdrew: Withdrawal by subject200
Withdrew: Death100
Withdrew: Met exclusion criteria200

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit.

Time frame:
Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)
Reported as:
Median · Weeks
Progression-Free Survival (PFS)
WeeksmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Progression-Free Survival (PFS)18.4 (15.7 to 24.4)21.4 (16.1 to 25.0)15.9 (14.1 to 16.4)
SecondaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes \[target or non-target\] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression.

Time frame:
Baseline until Disease Progression (Up to 95 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
percentage of participantsmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])14 (5.94 to 27.24)3.8 (0.47 to 13.21)3.8 (0.47 to 13.21)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.

Time frame:
Baseline Until Death from Any Cause (Up to 163 Weeks)
Reported as:
Median · Weeks
Overall Survival (OS)
WeeksmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Overall Survival (OS)53.6 (36.1 to 68.4)41.7 (28.4 to 60.3)42.0 (32.0 to 50.4)
SecondaryDuration of Response (DoR)

DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to \< 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.)

Time frame:
Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)
Reported as:
Median · Weeks
Duration of Response (DoR)
WeeksmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Duration of Response (DoR)35.6 (4.0 to NA)NA (NA to NA)NA (8.1 to NA)
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5

Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum.

Time frame:
Cycle 5, 1 Hour Post End of Infusion
Reported as:
Geometric mean · microgram/milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5
microgram/milliliter (µg/mL)mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Pharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5NA ± NA201 ± 88
SecondaryPharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 5

Trough (prior to infusion, Ctrough) concentrations measured in serum.

Time frame:
Cycle 5, Prior to Infusion
Reported as:
Geometric mean · µg/mL
Pharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 5
µg/mLmFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Pharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 553.6 ± 123146 ± 32
SecondaryMaximum Concentration (Cmax) at Day 8

Maximum concentration (Cmax) is the maximum peak concentration measured in blood plasma after drug infusion.

Time frame:
Day 8 (cycles 1 and 5)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) at Day 15

Cmax is the maximum peak concentration measured in blood plasma after drug infusion.

Time frame:
Day 15 (Cycles 1 and 5)

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Day 1

Cmin is the minimum peak concentration measured in blood plasma after drug infusion.

Time frame:
Day 1 (cycles 1, 5, 9, and 13)

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Day 4

Cmin is the minimum peak concentration measured in blood plasma after drug infusion.

Time frame:
Day 4 (cycles 1 and 5)

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Day 8

Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.

Time frame:
Day 8 (cycles 1 and 5)

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Day 15

Minimum concentration (Cmin) is the minimum peak concentration measured in blood plasma after drug infusion.

Time frame:
Day 15 (cycles 1 and 5)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Serum Ramucirumab Antibody Assessment

A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.

Time frame:
31 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Serum Ramucirumab Antibody Assessment
ParticipantsmFOLFOX-6 + Ramucirumab
Number of Participants With Serum Ramucirumab Antibody Assessment0
SecondarySerum Anti-Icrucumab Antibody Assessment

A sample will be considered positive for anti-icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-icrucumab antibody level seen in healthy untreated individuals.

Time frame:
31 Weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events

A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to 165 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
Any TEAE495252
Any SAE111812
Any Grade ≥3 AE303731
Any AE leading to discontinuation (any drug)61811

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mFOLFOX-637/49 (75.5%)11/49 (22.4%)48/49 (98%)
mFOLFOX-6 + Ramucirumab41/52 (78.8%)18/52 (34.6%)52/52 (100%)
mFOLFOX-6 + Icrucumab40/52 (76.9%)12/52 (23.1%)52/52 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
PyrexiaGeneral disorders0/491/523/52
VomitingGastrointestinal disorders2/490/522/52
SepsisInfections and infestations2/490/521/52
FatigueGeneral disorders0/492/521/52
Bile duct obstructionHepatobiliary disorders0/492/520/52
DehydrationMetabolism and nutrition disorders0/490/522/52
Diabetic ketoacidosisMetabolism and nutrition disorders0/490/522/52
Febrile neutropeniaBlood and lymphatic system disorders1/491/520/52
CataractEye disorders1/490/520/52
Abdominal painGastrointestinal disorders1/491/520/52
Most frequent other events
Showing 10 of 92
Most frequent other events
EventmFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + Icrucumab
FatigueGeneral disorders35/4945/5236/52
NauseaGastrointestinal disorders30/4924/5236/52
Peripheral sensory neuropathyNervous system disorders27/4925/5232/52
DiarrhoeaGastrointestinal disorders19/4930/5227/52
Oedema peripheralGeneral disorders5/4915/5229/52
VomitingGastrointestinal disorders17/4913/5227/52
AnorexiaMetabolism and nutrition disorders16/4920/5227/52
Abdominal painGastrointestinal disorders13/4916/5224/52
Temperature intoleranceGeneral disorders21/4913/5218/52
ConstipationGastrointestinal disorders12/4918/5219/52

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)mFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + IcrucumabTotal
Mean60.8 ± 9.2359.9 ± 10.9558.2 ± 10.1559.6 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)mFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + IcrucumabTotal
Female21212971
Male28312382
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + IcrucumabTotal
Hispanic or Latino0011
Not Hispanic or Latino495251152
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)mFOLFOX-6mFOLFOX-6 + RamucirumabmFOLFOX-6 + IcrucumabTotal
American Indian or Alaska Native0000
Asian75719
Native Hawaiian or Other Pacific Islander1001
Black or African American3104
White354545125
More than one race0101
Unknown or Not Reported3003
08

Study locations

17 sites
  • ImClone Investigational Site
    Cincinnati, Ohio 45242, United States
  • ImClone Investigational Site
    Columbia, South Carolina 29210, United States
  • ImClone Investigational Site
    Nashville, Tennessee 37232, United States
  • ImClone Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • ImClone Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • ImClone Investigational Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • ImClone Investigational Site
    Surrey, British Columbia V3V 1Z2, Canada
  • ImClone Investigational Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • ImClone Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • ImClone Investigational Site
    Hamilton, Ontario L8V 5C2, Canada
  • ImClone Investigational Site
    London, Ontario N6A 4L6, Canada
  • ImClone Investigational Site
    Mississauga, Ontario L5M 2N1, Canada
  • ImClone Investigational Site
    Oshawa, Ontario L1G 2B9, Canada
  • ImClone Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • ImClone Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • ImClone Investigational Site
    Windsor, Ontario N8W 2X3, Canada
  • ImClone Investigational Site
    Montreal, Quebec H2W 156, Canada
09

References and documents

Publications

  • Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati SR, Nasroulah F, Yang L, Ramdas N, Binder P, Strevel E. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol. 2016 Dec;27(12):2216-2224. doi: 10.1093/annonc/mdw412. Epub 2016 Oct 11. PubMed 27733377 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2019, 5 years 8 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 27, 2010
Start
Aug 2010
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results delay requested
Aug 30, 2010
Results first posted
Aug 6, 2019
Last update
Aug 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01111604
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
Aug 2010
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Aug 6, 2019
Last update
Aug 6, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Icrucumab

Start the discussion